GtoPdb Ligand ID: 8093

Synonyms: Ilumetri® | Ilumya® | MK-3222 | MK3222 | SCH-900222 | SCH900222 | SUNPG1623 | tildrakizumab-asmn
tildrakizumab is an approved drug (EMA & FDA (2018))
Compound class: Antibody
Comment: Tildrakizumab is a monoclonal antibody directed against the p19 subunit of IL-23 (IL-23A). It exhibits efficacy in treating psoriasis [1,4]. This biologic agent may be beneficial for patients who do not tolerate current antitumour necrosis factor (TNF) therapies.
1. Mease PJ. (2015)
Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
Curr Opin Rheumatol, 27 (2): 127-33. [PMID:25599143]
2. Presta LG, Beyer BM, Ingram RN, Orth P, Liu Y-H. (2011)
Engineered Anti-IL-23p19 Antibodies.
Patent number: US20110142853. Assignee: Schering Corporation. Priority date: 23/02/2007. Publication date: 16/06/2011.
3. Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Tha├ži D, Nograles K, Mehta A, Cichanowitz N, Li Q et al.. (2017)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Lancet, 390 (10091): 276-288. [PMID:28596043]
4. Tausend W, Downing C, Tyring S. (2014)
Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
J Cutan Med Surg, 18 (3): 156-69. [PMID:24800703]